论文部分内容阅读
目的：观察更昔洛韦对肾移植患者环孢菌素Ａ药代动力学参数的影响，以促进临床合理用药，提高肾移植存活率。方法：分别对１０例肾移植患者单用环孢菌素Ａ与合用更昔洛韦后环孢菌素Ａ的药代动力学参数进行研究和评价，采用荧光偏振免疫法测定各时刻环孢菌素Ａ血中浓度，３Ｐ８７程序拟合药代动力学参数，ｔ检验比较组间差异。结果：合用更昔洛韦后，环孢菌素ＡＫｅ，ｔ１／２（Ｋａ）分别由单用组的（０．１６±０．０４）ｈ－１和（１．３９±０．７６）ｈ降至（０．０９±０．０５）ｈ－１和（０．５０±０．３２）ｈ（Ｐ＜０．０５），ｔｍａｘ由（３．６７±０．７７）ｈ－１减至（２．００±０．７８）ｈ－１（Ｐ＜０．０１），ｔ１／２（Ｋｅ）由（４．０８±１．８５）ｈ－１增至（１０．５１±６．４２）ｈ－１，峰浓度ｃｍａｘ平均升高２７％。结论：更昔洛韦使肾移植患者对环孢菌素Ａ的吸收显著加快，而使环孢菌素Ａ在体内的消除减慢，对血中环孢菌素Ａ的峰浓度也有一定影响，揭示临床调整用药方案
Objective: To observe the effect of ganciclovir on the pharmacokinetic parameters of cyclosporin A in renal transplant recipients, in order to promote clinical rational use of drugs and improve the survival rate of renal allografts. Methods: The pharmacokinetic parameters of cyclosporin A combined with cyclosporin A in 10 renal transplant recipients were studied and evaluated. Fluorescence polarization immunoassay Serum concentration of A, 3P87 program fitted pharmacokinetic parameters, t test to compare the differences between groups. Results: Cyclosporine AKe and t1 / 2 (Ka) were increased from (0.16 ± 0.04) h-1 and (1.39 ± 0.76) h (0.09 ± 0.05) h-1 and (0.50 ± 0.32) h (P <0.05), and the tmax decreased from (3.67 ± 0.77) h-1 to 2.00 ± 0.78) h-1 (P <0.01), and t1 / 2 (Ke) increased from (4.08 ± 1.85) h-1 to (10.51 ± 6.42) h -1, the peak concentration of cmax increased by an average of 27%. CONCLUSIONS: Ganciclovir increases the absorption of cyclosporin A significantly faster in kidney transplant recipients, whereas depletion of cyclosporin A in the body slows down and also has some effect on the peak concentration of cyclosporine A in blood Clinical adjustment medication program